We are building upon successful foundational research that established a successful cure for PTSD in a rodent model. Our piloted PTSD treatment in rodents consists of a surgical intervention shortly after a traumatic event to decrease GluA1 levels in the amygdala to non-PTSD levels. Unlike existing PTSD treatments, which typically target symptoms, we target the biological cause of PTSD—an up-regulation of a chemical in the region of the brain responsible for fear learning. Testing of the cure in the rodent model effected a complete reversal of PTSD without amnesia for the triggering trauma.
We are developing non-invasive methods of delivery so that surgery is not necessary for the cure. Small molecule drug discovery and pre-clinical validation experiments have begun in Spring 2017. In vivo studies are expected to begin in late 2019.